{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:22:07Z","timestamp":1788906127768,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Continuous glucose monitoring (CGM) improves glycemic control and quality of life. Data on glycemic indices and fear of hypoglycemia (FoH) in newly diagnosed T1DM patients are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess the impact of initiating intermittently scanned CGM (isCGM) within 1\u20136 months of diagnosis on glycemic control and FoH in adults with T1DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects and methods<\/jats:title><jats:p>After wearing a blinded sensor for 14 days, participants were randomized (1:1) to either isCGM (intervention) or self-monitoring blood glucose (SMBG) with glucometers and blinded CGM (control). Primary outcomes were changes in time below 70 mg\/dl (TB70) and FoH, assessed in the Hypoglycemia Fear Survey (HFS). Main secondary outcomes included changes in mean glucose and time in range (TIR) from baseline to 4 weeks after randomization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The full analysis set included 23 patients (12 from the intervention group and 11 from the control group), aged 25.6 \u00b1 5.1 years (14 men, 9 women). All participants were on multiple daily insulin injections. TB70 changed from 2.42% to 2.25% in the intervention, and from 2.81% to 1.82% in the control group, and the between-therapy difference of 0.83% was insignificant. No difference between intervention and control groups in change in HFS-worry and HFS-behavior subscales between baseline and after 4 weeks was found (\u22121.6 \u00b1 3.2 and 1.0 \u00b1 2.2, respectively). The mean glucose levels changed from 7.03 mmol\/l to 6.73 mmol\/l and from 7.07 mmol\/l to 7.43 mmol\/l, in the intervention and control groups, respectively, which resulted in a between-therapy significant glucose difference of \u22120.66 mmol\/l. The mean TIR changed from 88.0% to 90.0% in the intervention group and from 85.2 to 84.1% in the control group\u2014the between-therapy difference was insignificant (3,1%). The study ended early due to CGM reimbursement policy changes, after which most patients eligible for the study could have isCGM reimbursed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In newly diagnosed T1DM adults, TIR is high and hypoglycemia risk is low. The study group was small; however, the data suggest that the use of isCGM soon after T1DM diagnosis could result in mean glucose decrease, but not in change in TB70 and FoH.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1503891","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:12:17Z","timestamp":1736399537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of the initiation of isCGM soon after type 1 diabetes mellitus diagnosis in adults on glycemic indices and fear of hypoglycemia: a randomized controlled trial"],"prefix":"10.3389","volume":"15","author":[{"given":"Jerzy","family":"Hohendorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Grzelka-Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Wrobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Lapinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Rokicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Stoltny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Strojek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Zozulinska-Ziolkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej T.","family":"Malecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S007","article-title":"7. Diabetes technology: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31142-0","article-title":"Advances in technology for management of type 1 diabetes","volume":"394","author":"Beck","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31535-5","article-title":"Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial","volume":"388","author":"Bolinder","year":"2016","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00061-X","article-title":"Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-based study","volume":"11","author":"Karges","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0133","article-title":"The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial","volume":"40","author":"Polonsky","year":"2017","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2109","article-title":"The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications\/Epidemiology of Diabetes Interventions and Complications cohort","volume":"36","author":"Jacobson","year":"2013","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.08.021","article-title":"Type 1 diabetes, quality of life, occupational status and education level - A comparative population-based study","volume":"121","author":"Nielsen","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1987","article-title":"New definition for the partial remission period in children and adolescents with type 1 diabetes","volume":"32","author":"Mortensen","year":"2009","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12413","article-title":"Factors contributing to partial remission in type 1 diabetes: analysis based on the insulin dose-adjusted HbA1c in 3657 children and adolescents from Germany and Austria","volume":"18","author":"Nagl","year":"2017","journal-title":"Pediatr Diabetes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13044","article-title":"Frequency, clinical characteristics, and determinants of partial remission in type 1 diabetes: Different patterns in children and adults","volume":"12","author":"Zhong","year":"2020","journal-title":"J Diabetes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107789","article-title":"Individual and diabetes presentation characteristics associated with partial remission status in children and adults evaluated up to 12 months following diagnosis of type 1 diabetes: An ADDRESS-2 (After Diagnosis Diabetes Research Support System-2) study analysis","volume":"155","author":"Humphreys","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03467.x","article-title":"Smoking and other factors associated with short-term partial remission of Type 1 diabetes in adults","volume":"29","author":"Pilacinski","year":"2012","journal-title":"Diabetes Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.600","article-title":"Immunological mechanisms associated with long-term remission of human type 1 diabetes","volume":"22","author":"Karges","year":"2006","journal-title":"Diabetes Metab Res Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e3207","DOI":"10.1002\/dmrr.3207","article-title":"The remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno-metabolic mechanisms","volume":"36","author":"Zhong","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/db20-1294-P","article-title":"Clinically significant hypoglycemia is rare in youth with T1D during partial clinical remission","volume":"69","author":"Addala","year":"2020","journal-title":"Diabetes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1343","article-title":"Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes","volume":"34","author":"Gonder-Frederick","year":"2011","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.3.626","article-title":"Assessing psychosocial distress in diabetes: development of the diabetes distress scale","volume":"28","author":"Polonsky","year":"2005","journal-title":"Diabetes Care"},{"key":"B20","article-title":"Diabetes treatment satisfaction questionnaire","volume-title":"Handbook of Psychology and Diabetes","author":"Bradley","year":"1994"},{"key":"B21","unstructured":"Rozporzadzenie Ministra Zdrowia z dnia 27 pazdziernika 2022 r. zmieniajace rozporzadzenie w sprawie wykazu wyrobow medycznych wydawanych na zlecenie (Dz.U. 2022 poz. 2319)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.1038\/s41598-023-34037-7","article-title":"Complete remission in children and adolescents with type 1 diabetes mellitus-prevalence and factors","volume":"13","author":"Podolakova","year":"2023","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.996933fdv","article-title":"Higher scanning frequency is correlated with less fear of hypoglycemia in type 1 diabetes patients using isCGM","volume":"13","author":"Hohendorff","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0034","article-title":"Intermittently scanned continuous glucose monitoring data of polish patients from real-life conditions: more scanning and better glycemic control compared to worldwide data","volume":"23","author":"Hohendorff","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0019","article-title":"Continuous glucose monitoring in adults with type 1 diabetes: real-world data from the german\/Austrian prospective diabetes follow-up registry","volume":"22","author":"Sandig","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0470","article-title":"Transitioning of people with type 1 diabetes from multiple daily injections and self-monitoring of blood glucose directly to miniMed 780G advanced hybrid closed-loop system: A two-center, randomized, controlled study","volume":"45","author":"Matejko","year":"2022","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.907517","article-title":"Early initiation of intermittently scanned continuous glucose monitoring in a pediatric population with type 1 diabetes: A real world study","volume":"13","author":"Franceschi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab522","article-title":"Clinically serious hypoglycemia is rare and not associated with time-in-range in youth with new-onset type 1 diabetes","volume":"106","author":"Addala","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3614","article-title":"Effects of intermittently scanned continuous glucose monitoring in adult type 1 diabetes patients with suboptimal glycaemic control: A multi-centre randomized controlled trial","volume":"39","author":"Yan","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102509","article-title":"Impact of intermittently scanned continuous glucose monitoring on quality of life and glycaemic control in persons with type 1 diabetes: A 12-month follow-up study in real life","volume":"16","author":"Duarte","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1610","article-title":"Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): A prospective observational real-world cohort study","volume":"43","author":"Charleer","year":"2020","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2022.0452","article-title":"Sustained impact of intermittently scanned continuous glucose monitoring on treatment satisfaction and severe hypoglycemia in adults with type 1 diabetes (FUTURE): an analysis in people with normal and impaired awareness of hypoglycemia","volume":"25","author":"Charleer","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-022-01884-1","article-title":"Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care","volume":"59","author":"Boscari","year":"2022","journal-title":"Acta Diabetol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102119","article-title":"Effect of diabetes technologies on the fear of hypoglycaemia among people living with type 1 diabetes: a systematic review and meta-analysis","volume":"62","author":"Talbo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4527-5","article-title":"Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial","volume":"61","author":"Oskarsson","year":"2018","journal-title":"Diabetologia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274626","article-title":"Long-term glucose-lowering effect of intermittently scanned continuous glucose monitoring for type 1 diabetes patients in poor glycaemic control from Region North Denmark: An observational real-world cohort study","volume":"17","author":"Jensen","year":"2022","journal-title":"PloS One"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1503891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:12:20Z","timestamp":1736399540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1503891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":36,"alternative-id":["10.3389\/fendo.2024.1503891"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1503891","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"article-number":"1503891"}}